Evotec Secures $2.9 Million Grant to Advance Early Drug Safety Testing Using Human Stem Cell Technology

Detailed summary
Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that it has been awarded a new $2.9 million grant by the Gates Foundation to support continued use of its human stem cell-based New Approach Methodologies (NAMs) for identifying potential safety risks to fetal development in novel drug candidates.
HAMBURG, Germany, Nov. 16, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that it has been awarded a new $2.9 million grant by the Gates Foundation to support continued use of its human stem cell-based New Approach Methodologies (NAMs) for identifying potential safety risks to fetal development in novel drug candidates. The funding extends a project initiated in 2023 for a further three years, providing researchers working on global health programs with continued access to technology that can help assess potential risks earlier in drug discovery.
Dr. Joanna Holbrook, Chief Scientific Officer of Evotec, said: "Identifying potential safety risks early in the drug development process is essential to the efficient advancement of better medicines for global health priorities. Our platform allows researchers to investigate potential effects on prenatal development based on the behavior of human cells, helping them make better-informed decisions about which drug candidates to pursue and minimizing the risk of costly and time-consuming changes in course later in the process.
Evotec's platform combines human induced pluripotent stem cell (hiPSC) models with industrial-scale screening capabilities to model aspects of human development and to identify compounds that may pose developmental risks.
Over the course of the initial three-year collaboration, more than 5,000 compounds were screened across nine grantee programs, highlighting the platform's ability to generate human-relevant safety data at scale. The development and validation of the platform are described in a recent bioRxiv preprint.
Evotec's human stem cell-based platform forms part of its broader capabilities in New Approach Methodologies, which can potentially reduce reliance on animal testing and help improve research efficiency.
Evotec is advancing a broad portfolio of human-relevant NAMs designed to support drug discovery and development.
Evotec's human iPSC-based…
Opening of the article, excerpted from Yahoo Finance. To read the rest, open the article on the publisher's site.
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (finance.yahoo.com)




